Loading organizations...
§ Private Profile · Cambridge, UK
Zetta Genomics is a technology company.
Zetta Genomics has raised $7.3M across 3 funding rounds.
Key people at Zetta Genomics.
Zetta Genomics has raised $7.3M in total across 3 funding rounds.
Zetta Genomics offers XetaBase, a genomic-native platform managing and analyzing genomic data. It streamlines clinical diagnostics, scales testing, and identifies trial candidates. XetaBase processes, annotates, and enriches genomic information, enabling continuous re-interpretation for insights. The platform utilizes open-source OpenCB software.
Ignacio Medina founded Zetta Genomics in 2017, a spin-out from the University of Cambridge. Medina’s expertise, including co-developing OpenCB and contributing to the 100,000 Genomes Project, provided the core insight. He recognized the need for robust solutions managing large genomic datasets, shaping its specialized approach.
XetaBase serves healthcare systems, life sciences companies, research institutions, and health-tech innovators, alongside bioinformaticians and clinicians. Zetta Genomics empowers genomic data application to improve global health outcomes. The company envisions unlocking genomic information's full potential, advancing precision medicine via scalable analytics for populations.
Zetta Genomics has raised $7.3M in total across 3 funding rounds.
Zetta Genomics's investors include APEX Ventures, Elaine Loukes, Marc Subirats, Louise Warme, Nina Capital, Cambridge Enterprise.
Zetta Genomics has raised $7.3M across 3 funding rounds. Most recently, it raised $2.3M Seed Extension in February 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 8, 2024 | $2.3M Seed Plus | — | APEX Ventures, Elaine Loukes, Marc Subirats, Louise Warme | Announced |
| Apr 1, 2023 | $2M Seed | Nina Capital | APEX Ventures, Cambridge Enterprise | Announced |
| Jan 1, 2022 | $3M Seed | — | Nina Capital | Announced |
Key people at Zetta Genomics.
Zetta Genomics is a technology company specializing in genomic data management and precision medicine solutions. Its flagship product, XetaBase, is a genomic-native platform designed to store, scale, and interpret vast amounts of genomic and clinical data for research, clinical, and pharmaceutical applications. The company primarily serves bioinformaticians, clinicians, researchers, and pharmaceutical R&D teams, addressing the critical challenge of managing the growing volume and complexity of genomic data to enable faster, more insightful decision-making in healthcare and biomedical research. Zetta Genomics has demonstrated strong growth momentum, expanding its team and customer base globally while securing multiple rounds of funding to scale its technology and market reach[1][2][3].
Founded in 2018 as a spin-out from the University of Cambridge and Genomics England, Zetta Genomics emerged from the need identified during the 100,000 Genomes Project to handle genomic data's volume and complexity more effectively. The company’s co-founder, Ignacio Medina, and his team developed OpenCB, an open-source genomic data solution, which laid the groundwork for XetaBase. Early traction came from collaborations with leading research and pharmaceutical organizations, and the company has since grown through accelerator programs, seed funding rounds, and strategic partnerships, evolving from managed services to a scalable cloud-based platform deployed on AWS and Azure[1][3][4].
Zetta Genomics rides the wave of precision medicine and the increasing affordability of genomic sequencing, which is generating unprecedented volumes of complex data. The timing is critical as healthcare and pharmaceutical sectors demand scalable, efficient data management to translate genomic insights into clinical outcomes. Market forces such as advances in cloud computing, AI-driven analytics, and global initiatives in genomic research favor Zetta’s growth. By enabling real-time, large-scale genomic data analysis, Zetta Genomics influences the broader ecosystem by accelerating discovery, improving collaboration, and supporting the shift from reactive to predictive and personalized healthcare[1][2][3].
Looking ahead, Zetta Genomics is poised to expand its global footprint and deepen its impact on precision medicine through continuous platform enhancements and strategic partnerships. Trends such as increasing genomic data generation, integration of multi-omics data, and AI-powered interpretation will shape its journey. The company’s ability to scale with cloud infrastructure and maintain cutting-edge genomic data capabilities positions it to become a foundational technology provider in healthcare and life sciences. Its influence is likely to grow as precision medicine becomes mainstream, driving better health outcomes worldwide[2][3][4].
